Healthcare

OncoSil Medical Limited (ASX:OSL) develops a single-use brachytherapy device that places radioactive phosphorus-32 microparticles directly inside pancreatic tumours. The device is intended for use alongside chemotherapy in patients with locally advanced, unresectable pancreatic cancer. During 2026, the company reported clinical findings and regulatory developments …

Osteopore Limited (ASX:OSX) uses a porous implant structure intended to support the growth of new tissue. The polymer scaffold gradually resorbs as healing progresses, unlike a permanent implant designed to remain in place. The technology’s clinical role depends on the procedure, anatomical site and …

Patrys Limited (ASX:PAB) develops an injectable formulation of quetiapine for potential use in delirium and researches deoxymab antibodies for cancer and inflammatory conditions. Its 2026 activity has centred on starting human evaluation of RLS-2202, while preserving research options for its antibody platform. The distinction …

HMBD-002 is designed to inhibit VISTA, an immune checkpoint regulator involved in interactions between tumours and immune cells. Blocking this pathway is intended to affect the immune environment around cancer. That biological rationale is not equivalent to demonstrated treatment efficacy, and clinical studies are …

In healthcare and life-sciences markets, a promising technology is only the beginning. The harder test is turning a defined scientific or commercial ambition into repeatable progress. Cynata Therapeutics Limited (ASX:CYP) is navigating that test through biomanufacturing economics & global partnering. Its immediate agenda centres …

In healthcare and life-sciences markets, a promising technology is only the beginning. The harder test is turning a defined scientific or commercial ambition into repeatable progress. Ceryvyn Therapeutics Limited (ASX:CYV) is navigating that test through commercialisation pathways & orphan market economics. Its immediate agenda …

In healthcare and life-sciences markets, a promising technology is only the beginning. The harder test is turning a defined scientific or commercial ambition into repeatable progress. Dimerix Limited (ASX:DXB) is navigating that test through global orphan licensing & milestone monetisation. Its immediate agenda centres …